Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts

B. Geoerger, J. Grill, P. Opolon, J. Morizet, G. Aubert, Y. Lecluse, V. W. Van Beusechem, W. R. Gerritsen, D. H. Kirn, G. Vassal

Research output: Contribution to journalArticle

Abstract

In spite of aggressive surgery, irradiation and/or chemotherapy, treatment of malignant gliomas remains a major challenge in adults and children due to high treatment failure. We have demonstrated significant cell lysis and antitumour activity of the EIB-55 kDa-gene-deleted adenovirus ONYX-015 (dl1520, CI-1042; ONYX Pharmaceuticals) in subcutaneous human malignant glioma xenografts deriving from primary tumours. Here, we show the combined efficacy of this oncolytic therapy with radiation therapy. Total body irradiation (5 Gy) of athymic nude mice prior to intratumoral injections of ONYX-015 1 x 10 8 PFU daily for 5 consecutive days yielded additive tumour growth delays in the p53 mutant xenograft IGRG88. Radiation therapy was potentiated in the p53 functional tumour IGRG121 with a 'subtherapeutic' dose of 1 x 10 7 PFU daily for 5 consecutive days, inducing significant tumour growth delay, 90% tumour regression and 50% tumour-free survivors 4 months after treatment. These potentiating effects were not due to increased adenoviral infectivity or replication. Furthermore, cell lysis and induction of apoptosis, the major mechanisms for adenoviral antitumour activity, did not play a major role in the combined treatment strategy. Interestingly, the oncolytic adenovirus seemed to accelerate radiation-induced tumour fibrosis. Potentiating antitumour activity suggests the development of this combined treatment for these highly malignant tumours.

Original languageEnglish (US)
Pages (from-to)577-584
Number of pages8
JournalBritish Journal of Cancer
Volume89
Issue number3
DOIs
StatePublished - Aug 4 2003
Externally publishedYes

Fingerprint

Heterografts
Adenoviridae
Glioma
Radiotherapy
Neoplasms
Nude Mice
Therapeutics
ONYX015
Whole-Body Irradiation
Growth
Treatment Failure
Fibrosis
Radiation
Apoptosis
Drug Therapy
Injections
Pharmaceutical Preparations
Genes

Keywords

  • Adenoviral cytolysis
  • Brain tumour
  • Radiosensitization
  • Xenografts

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts. / Geoerger, B.; Grill, J.; Opolon, P.; Morizet, J.; Aubert, G.; Lecluse, Y.; Van Beusechem, V. W.; Gerritsen, W. R.; Kirn, D. H.; Vassal, G.

In: British Journal of Cancer, Vol. 89, No. 3, 04.08.2003, p. 577-584.

Research output: Contribution to journalArticle

Geoerger, B, Grill, J, Opolon, P, Morizet, J, Aubert, G, Lecluse, Y, Van Beusechem, VW, Gerritsen, WR, Kirn, DH & Vassal, G 2003, 'Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts', British Journal of Cancer, vol. 89, no. 3, pp. 577-584. https://doi.org/10.1038/sj.bjc.6601102
Geoerger, B. ; Grill, J. ; Opolon, P. ; Morizet, J. ; Aubert, G. ; Lecluse, Y. ; Van Beusechem, V. W. ; Gerritsen, W. R. ; Kirn, D. H. ; Vassal, G. / Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts. In: British Journal of Cancer. 2003 ; Vol. 89, No. 3. pp. 577-584.
@article{e346b13bf29841499f93566fa348890d,
title = "Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts",
abstract = "In spite of aggressive surgery, irradiation and/or chemotherapy, treatment of malignant gliomas remains a major challenge in adults and children due to high treatment failure. We have demonstrated significant cell lysis and antitumour activity of the EIB-55 kDa-gene-deleted adenovirus ONYX-015 (dl1520, CI-1042; ONYX Pharmaceuticals) in subcutaneous human malignant glioma xenografts deriving from primary tumours. Here, we show the combined efficacy of this oncolytic therapy with radiation therapy. Total body irradiation (5 Gy) of athymic nude mice prior to intratumoral injections of ONYX-015 1 x 10 8 PFU daily for 5 consecutive days yielded additive tumour growth delays in the p53 mutant xenograft IGRG88. Radiation therapy was potentiated in the p53 functional tumour IGRG121 with a 'subtherapeutic' dose of 1 x 10 7 PFU daily for 5 consecutive days, inducing significant tumour growth delay, 90{\%} tumour regression and 50{\%} tumour-free survivors 4 months after treatment. These potentiating effects were not due to increased adenoviral infectivity or replication. Furthermore, cell lysis and induction of apoptosis, the major mechanisms for adenoviral antitumour activity, did not play a major role in the combined treatment strategy. Interestingly, the oncolytic adenovirus seemed to accelerate radiation-induced tumour fibrosis. Potentiating antitumour activity suggests the development of this combined treatment for these highly malignant tumours.",
keywords = "Adenoviral cytolysis, Brain tumour, Radiosensitization, Xenografts",
author = "B. Geoerger and J. Grill and P. Opolon and J. Morizet and G. Aubert and Y. Lecluse and {Van Beusechem}, {V. W.} and Gerritsen, {W. R.} and Kirn, {D. H.} and G. Vassal",
year = "2003",
month = "8",
day = "4",
doi = "10.1038/sj.bjc.6601102",
language = "English (US)",
volume = "89",
pages = "577--584",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts

AU - Geoerger, B.

AU - Grill, J.

AU - Opolon, P.

AU - Morizet, J.

AU - Aubert, G.

AU - Lecluse, Y.

AU - Van Beusechem, V. W.

AU - Gerritsen, W. R.

AU - Kirn, D. H.

AU - Vassal, G.

PY - 2003/8/4

Y1 - 2003/8/4

N2 - In spite of aggressive surgery, irradiation and/or chemotherapy, treatment of malignant gliomas remains a major challenge in adults and children due to high treatment failure. We have demonstrated significant cell lysis and antitumour activity of the EIB-55 kDa-gene-deleted adenovirus ONYX-015 (dl1520, CI-1042; ONYX Pharmaceuticals) in subcutaneous human malignant glioma xenografts deriving from primary tumours. Here, we show the combined efficacy of this oncolytic therapy with radiation therapy. Total body irradiation (5 Gy) of athymic nude mice prior to intratumoral injections of ONYX-015 1 x 10 8 PFU daily for 5 consecutive days yielded additive tumour growth delays in the p53 mutant xenograft IGRG88. Radiation therapy was potentiated in the p53 functional tumour IGRG121 with a 'subtherapeutic' dose of 1 x 10 7 PFU daily for 5 consecutive days, inducing significant tumour growth delay, 90% tumour regression and 50% tumour-free survivors 4 months after treatment. These potentiating effects were not due to increased adenoviral infectivity or replication. Furthermore, cell lysis and induction of apoptosis, the major mechanisms for adenoviral antitumour activity, did not play a major role in the combined treatment strategy. Interestingly, the oncolytic adenovirus seemed to accelerate radiation-induced tumour fibrosis. Potentiating antitumour activity suggests the development of this combined treatment for these highly malignant tumours.

AB - In spite of aggressive surgery, irradiation and/or chemotherapy, treatment of malignant gliomas remains a major challenge in adults and children due to high treatment failure. We have demonstrated significant cell lysis and antitumour activity of the EIB-55 kDa-gene-deleted adenovirus ONYX-015 (dl1520, CI-1042; ONYX Pharmaceuticals) in subcutaneous human malignant glioma xenografts deriving from primary tumours. Here, we show the combined efficacy of this oncolytic therapy with radiation therapy. Total body irradiation (5 Gy) of athymic nude mice prior to intratumoral injections of ONYX-015 1 x 10 8 PFU daily for 5 consecutive days yielded additive tumour growth delays in the p53 mutant xenograft IGRG88. Radiation therapy was potentiated in the p53 functional tumour IGRG121 with a 'subtherapeutic' dose of 1 x 10 7 PFU daily for 5 consecutive days, inducing significant tumour growth delay, 90% tumour regression and 50% tumour-free survivors 4 months after treatment. These potentiating effects were not due to increased adenoviral infectivity or replication. Furthermore, cell lysis and induction of apoptosis, the major mechanisms for adenoviral antitumour activity, did not play a major role in the combined treatment strategy. Interestingly, the oncolytic adenovirus seemed to accelerate radiation-induced tumour fibrosis. Potentiating antitumour activity suggests the development of this combined treatment for these highly malignant tumours.

KW - Adenoviral cytolysis

KW - Brain tumour

KW - Radiosensitization

KW - Xenografts

UR - http://www.scopus.com/inward/record.url?scp=0042477562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042477562&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6601102

DO - 10.1038/sj.bjc.6601102

M3 - Article

C2 - 12888833

AN - SCOPUS:0042477562

VL - 89

SP - 577

EP - 584

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 3

ER -